2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Top Cited Papers
Open Access
- 31 May 2019
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 78 (6), 736-745
- https://doi.org/10.1136/annrheumdis-2019-215089
Abstract
Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.Keywords
Funding Information
- European League Against Rheumatism
This publication has 156 references indexed in Scilit:
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals Of The Rheumatic Diseases, 2012
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals Of The Rheumatic Diseases, 2012
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnnals Of The Rheumatic Diseases, 2012
- Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patientsGynecological Endocrinology, 2012
- Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis TrialAnnals Of The Rheumatic Diseases, 2010
- AGREE II: advancing guideline development, reporting and evaluation in health careCMAJ : Canadian Medical Association Journal, 2010
- European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studiesAnnals Of The Rheumatic Diseases, 2009
- Prednisone, Lupus Activity, and Permanent Organ DamageThe Journal of Rheumatology, 2009
- Successful Treatment of Class V+IV Lupus Nephritis with Multitarget TherapyJournal of the American Society of Nephrology, 2008
- Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosusAnnals Of The Rheumatic Diseases, 2007